DHT-U Fair Value & Analysis
Healthcare · CA · Market cap $700M
Fair value as of: Jul 12, 2026
From 8 valuation models · updated 9 days ago
Fair value updated Jul 12, 2026, revised from $14.92 to $10.95 (−26.6%) since Jun 24, 2026. Share price +2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $9.84 – $12.95 · fair‑value band $10.95 – $15.69 · the $12.87 price screens above the $10.95 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
DHT-U (DHT-U) currently trades at $12.87, while our model-based Fair Value estimate is $10.95, implying the stock looks roughly 14.9% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, DHT-U generated revenue of $192M at a net margin of -26.3%. Revenue declined 3.5% year over year. It earns a return on equity of -10.5%. Net debt stands at $440M. Fundamentals as of Jul 12, 2026
Our scenario range runs from $10.95 (bear case) to $15.69 (bull case); at $12.87, the current price sits within that range. The share trades near its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -15%, DHT-U screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DHT-U reported revenue of $195M in FY2025 versus $73.3M in FY2021, a compound +27.7%/yr. Reported net income was −$51.4M in FY2025.
Is DHT-U fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
| Mankind Pharma Limited MANKIND | ₹2,376 | ₹1,085 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DHT-U undervalued?
What is the fair value of DHT-U?
What is the quality score of DHT-U?
What is the revenue of DHT-U?
What is the net profit margin of DHT-U?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full DHT-U analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.